CRIS Current Research Information System

ALTAVILLA, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.926
NA - Nord America 876
EU - Europa 391
SA - Sud America 137
AF - Africa 58
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.394
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 850
SG - Singapore 538
VN - Vietnam 463
CN - Cina 456
HK - Hong Kong 188
IT - Italia 113
BR - Brasile 107
KR - Corea 91
BD - Bangladesh 62
DE - Germania 62
FR - Francia 48
NL - Olanda 39
FI - Finlandia 33
IN - India 32
JP - Giappone 27
GB - Regno Unito 23
SC - Seychelles 23
SE - Svezia 21
AR - Argentina 13
PH - Filippine 11
IQ - Iraq 10
MX - Messico 10
AT - Austria 9
CA - Canada 9
IE - Irlanda 8
CI - Costa d'Avorio 7
ID - Indonesia 7
TH - Thailandia 7
TR - Turchia 7
CO - Colombia 6
ES - Italia 6
PL - Polonia 6
RU - Federazione Russa 6
AU - Australia 5
SA - Arabia Saudita 5
TW - Taiwan 5
ZA - Sudafrica 5
KE - Kenya 4
PK - Pakistan 4
CL - Cile 3
EC - Ecuador 3
HN - Honduras 3
MA - Marocco 3
UZ - Uzbekistan 3
AL - Albania 2
BE - Belgio 2
BG - Bulgaria 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
JO - Giordania 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
PY - Paraguay 2
TG - Togo 2
TN - Tunisia 2
UA - Ucraina 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GT - Guatemala 1
JM - Giamaica 1
KG - Kirghizistan 1
LT - Lituania 1
LY - Libia 1
MN - Mongolia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.394
Salva come PNG Salva come JPEG
Città #
Singapore 368
Hefei 200
San Jose 175
Hong Kong 167
Ho Chi Minh City 130
Hanoi 128
Santa Clara 118
Ashburn 115
Seoul 85
Los Angeles 62
Beijing 60
Boardman 52
Buffalo 32
Da Nang 32
New York 31
Chandler 27
Helsinki 27
Tokyo 26
Lauterbourg 24
Bologna 20
Bengaluru 18
Rome 18
Haiphong 17
Munich 16
Council Bluffs 14
Falkenstein 11
Frankfurt am Main 11
Nuremberg 10
Shenzhen 9
Dublin 8
London 8
Abidjan 7
Dallas 7
Guangzhou 7
Shanghai 7
Baghdad 6
Chicago 6
Rio de Janeiro 6
Thái Nguyên 6
Tongling 6
Turin 6
Düsseldorf 5
Nha Trang 5
Redondo Beach 5
Warsaw 5
Bexley 4
Biên Hòa 4
Bắc Ninh 4
Bến Tre 4
Changsha 4
Charlotte 4
Genoa 4
Johannesburg 4
Lappeenranta 4
Mexico City 4
Milan 4
Nairobi 4
Orem 4
Phoenix 4
Princeton 4
Salt Lake City 4
San Francisco 4
Santo André 4
Stockholm 4
São Paulo 4
Wuhan 4
Bangkok 3
Brooklyn 3
Bắc Giang 3
Curitiba 3
Denver 3
Florence 3
Harbin 3
Huế 3
Jakarta 3
Lang Son 3
Marseille 3
Melbourne 3
Ninh Bình 3
Pescara 3
Recife 3
Tampa 3
Vienna 3
Việt Trì 3
Vũng Tàu 3
Addis Ababa 2
Ankara 2
Ann Arbor 2
Athens 2
Baoding 2
Bari 2
Berlin 2
Bern 2
Bogotá 2
Bolzano 2
Brussels 2
Busto Arsizio 2
Bảo Lộc 2
Camden 2
Cao Lanh 2
Totale 2.274
Salva come PNG Salva come JPEG
Nome #
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 215
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 201
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 193
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 157
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 147
PATIENT'S ATTITUDES TOWARDS TREATMENT IN ADVANCED CANCER: HOW THESE ARE IDENTIFIED FROM THEIR PHYSICIAN? 109
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 108
CAR-T cell therapy: A potential new strategy against prostate cancer 103
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) 101
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 100
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 97
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 96
RELATIONSHIP BETWEEN ENZALUTAMIDE ACTIVITY AND PREVIOUS ANTIANDROGEN WITHDRAWAL SYNDROME (AWS) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 89
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 89
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses 88
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 87
BENEFIT OF POST-DOCETAXEL TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH POOR PERFORMANCE STATUS 86
KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 85
Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC) 81
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 76
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate 69
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 68
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 66
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 65
ERLOTINIB RELATED TOXICITY IN ELDERLY PATIENTS AFFECTED BY NON-SMALL CELL LUNG CANCER (NSCLC) 65
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone 64
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 64
Clinical and pathological features of primary renal synovial sarcoma: Analysis of 64 cases from 11 years of medical literature 62
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents 62
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma 62
Visceral disease in castration-resistant prostate cancer 59
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 58
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 49
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies 47
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation 45
Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney 39
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 35
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 27
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 27
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone 24
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 20
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules 20
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view 19
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma 19
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert 18
null 2
Totale 3.463
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 0 0 0 6 1 1 10 12 9
2022/202362 4 10 2 10 7 9 0 1 11 0 3 5
2023/202440 2 3 1 0 1 6 0 15 5 1 2 4
2024/2025875 55 84 41 46 175 54 34 27 7 67 46 239
2025/20262.447 191 302 180 206 212 49 415 149 393 123 131 96
Totale 3.463